Triumvira Immunologics
Chemicals & Related Products · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
9433 FM 2244 Rd Bldg I Ste 240, Austin, ...Phone Number
(512) 790-0222Website
www.triumvira.comRevenue
$24 MillionIndustry
About Triumvira Immunologics
Triumvira Immunologics specializes in engineered T cell therapies aimed at empowering the body's natural defenses against life-threatening cancers. Their proprietary T cell Antigen Coupler (TAC) platform enhances the immune response by enabling T cells to target and destroy tumor cells through natural activation. The company is developing a robust pipeline of TAC-based therapeutic candidates applicable across a wide range of liquid and solid tumors. Triumvira leverages advanced manufacturing technologies to ensure optimum product quality in their innovative cancer therapies.Explore more
Triumvira Immunologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Triumvira Immunologics
Compare insights from companies similar to Triumvira Immunologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Triumvira Immunologics Tech Stack
A closer look at the technologies used by Triumvira Immunologics
See more technologies
Top Chemicals & Related Products Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Triumvira Immunologics
Sign Up For FreeTo access detailed company insights
Triumvira Immunologics specializes in engineered T cell therapies aimed at empowering the body's natural defenses against life-threatening cancers. Their proprietary T cell Antigen Coupler (TAC) platform enhances the immune response by enabling T cells to target and destroy tumor cells through natural activation. The company is developing a robust... Read More
